Cargando…

Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma

INTRODUCTION: Little is known of the function and clinical significance of intratumoral dysregulation of xenobiotic-metabolizing enzyme expression in breast cancer. One molecular mechanism proposed to explain tamoxifen resistance is altered tamoxifen metabolism and bioavailability. METHODS: To test...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bièche, Ivan, Girault, Igor, Urbain, Estelle, Tozlu, Sengül, Lidereau, Rosette
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2004
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC400681/ https://www.ncbi.nlm.nih.gov/pubmed/15084249 http://dx.doi.org/10.1186/bcr784

Ejemplares similares

Identification of a three-gene expression signature of poor-prognosis breast carcinoma
por: Bièche, Ivan, et al.
Publicado: (2004)

Prognostic value of maspin mRNA expression in ERα-positive postmenopausal breast carcinomas
por: Bièche, I, et al.
Publicado: (2003)

Update on inflammatory breast cancer
por: Lerebours, Florence, et al.
Publicado: (2005)

Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy
por: Bièche, Ivan, et al.
Publicado: (2011)

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)

Estrogen mimicking effects of xenobiotics in fish
por: Bjerregaard, Poul
Publicado: (2012)

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
por: Wegman, Pia, et al.
Publicado: (2005)

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
por: Gjerde, Jennifer, et al.
Publicado: (2010)

Estrogen receptor alpha in the brain mediates tamoxifen-induced changes in physiology in mice
por: Zhang, Zhi, et al.
Publicado: (2021)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
por: Nordenskjöld, Anna, et al.
Publicado: (2016)

Triclocarban Mediates Induction of Xenobiotic Metabolism through Activation of the Constitutive Androstane Receptor and the Estrogen Receptor Alpha
por: Yueh, Mei-Fei, et al.
Publicado: (2012)

MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?
por: Cizeron-Clairac, Geraldine, et al.
Publicado: (2015)

Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer
por: Madeira, Marcelo, et al.
Publicado: (2013)

NF-kappa B genes have a major role in Inflammatory Breast Cancer
por: Lerebours, Florence, et al.
Publicado: (2008)

Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer
por: Aydiner, Adnan, et al.
Publicado: (2008)

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012)

Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment
por: Beelen, Karin, et al.
Publicado: (2014)

Gene Expression Profiling Reveals New Aspects of PIK3CA Mutation in ERalpha-Positive Breast Cancer: Major Implication of the Wnt Signaling Pathway
por: Cizkova, Magdalena, et al.
Publicado: (2010)

Relative potency of xenobiotic estrogens in an acute in vivo mammalian assay.
por: Milligan, S R, et al.
Publicado: (1998)

FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer
por: Wang, Jinhua, et al.
Publicado: (2016)

The rate of estrogen receptor‐conversion associated with tumor progression in estrogen receptor‐positive breast cancer patients following adjuvant Tamoxifen administration
por: Djahansouzi, Sirus, et al.
Publicado: (2021)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
por: Bostner, Josefine, et al.
Publicado: (2012)

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids
por: Francini, G, et al.
Publicado: (2006)

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
por: Weiner, M., et al.
Publicado: (2013)

p-Nonyl-phenol: an estrogenic xenobiotic released from "modified" polystyrene.
por: Soto, A M, et al.
Publicado: (1991)

Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
por: Alkner, S., et al.
Publicado: (2017)

Adjuvant tamoxifen for early breast cancer.
por: Smith, I.
Publicado: (1988)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

Association of Over-Expressed Estrogen Receptor Alpha with Development of Tamoxifen Resistant Hyperplasia and Adenocarcinomas in Genetically Engineered Mice
por: Miermont, Anne M, et al.
Publicado: (2012)

Vitellogenin induction by xenobiotic estrogens in the red-eared turtle and African clawed frog.
por: Palmer, B D, et al.
Publicado: (1995)

Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer
por: Lee, Eun-Shin, et al.
Publicado: (2016)

Survival Benefit of Tamoxifen in Estrogen Receptor-Negative and Progesterone Receptor-Positive Low Grade Breast Cancer Patients
por: Yang, Li-Heng, et al.
Publicado: (2012)

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial
por: Trialists' Group, The ATAC
Publicado: (2001)

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot
por: Beelen, Karin, et al.
Publicado: (2018)

PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups
por: Cizkova, Magdalena, et al.
Publicado: (2012)

A Role for Estrogen Receptor Phosphorylation in the Resistance to Tamoxifen
por: de Leeuw, Renée, et al.
Publicado: (2011)

Tamoxifen non-estrogen receptor mediated molecular targets
por: Bogush, Tatiana, et al.
Publicado: (2012)

Adjuvant tamoxifen for male breast cancer (MBC).
por: Ribeiro, G., et al.
Publicado: (1992)

Catalpol Inhibits Macrophage Polarization and Prevents Postmenopausal Atherosclerosis Through Regulating Estrogen Receptor Alpha
por: Chen, Qi, et al.
Publicado: (2021)

HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women
por: Wege, Anja Kathrin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_thg019h5aot1gbk543cboedr52